Hormone Sensitive Prostate Cancer Clinical Trials

5 recruiting

Hormone Sensitive Prostate Cancer Trials at a Glance

6 actively recruiting trials for hormone sensitive prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Trento, Padova, and Nanjing. Lead sponsors running hormone sensitive prostate cancer studies include AdvanCell Pty Limited, Pfizer, and Santa Chiara Hospital.

Browse hormone sensitive prostate cancer trials by phase

Treatments under study

About Hormone Sensitive Prostate Cancer Clinical Trials

Looking for clinical trials for Hormone Sensitive Prostate Cancer? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hormone Sensitive Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hormone Sensitive Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled295 locationsNCT07028853
Recruiting
Phase 1Phase 2

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
AdvanCell Pty Limited100 enrolled3 locationsNCT05720130
Recruiting
Phase 2

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Prostate CancerProstate AdenocarcinomaHormone Sensitive Prostate Cancer
University of Miami34 enrolled1 locationNCT06392295
Recruiting
Phase 3

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Prostate CancerMetastatic CancerProstate Cancer Metastatic+4 more
Universitaire Ziekenhuizen KU Leuven873 enrolled1 locationNCT05352178
Recruiting

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Prostate CancerMetastatic TumorHormone Sensitive Prostate Cancer
Santa Chiara Hospital3,000 enrolled3 locationsNCT06473259
Recruiting
Phase 3

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Chemotherapy EffectMetastatic Prostate CancerHormone Sensitive Prostate Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05983783